Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAYPOINT: Tezepelumab in severe chronic rhinosinusitis with nasal polyps
CTR20210581Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tezepelumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by AstraZeneca. Started Mar 2021; status: completed.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20210581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210581.